S100A8 and S100A9 in Hematologic Malignancies: From Development to Therapy
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms241713382 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Farnaz Razmkhah und 4 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA. Hauptthemen laut MEDLINE: Calgranulin A, Calgranulin B, Hematologic Neoplasms. Die Arbeit wurde bisher 28-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, Amy Strelzer Manasevit Research Program, Foundation for Barnes-Jewish Hospital Cancer Frontier Fund.
Abstract (Originalsprache)
S100A8 and S100A9 are multifunctional proteins that can initiate various signaling pathways and modulate cell function both inside and outside immune cells, depending on their receptors, mediators, and molecular environment. They have been reported as dysregulated genes and proteins in a wide range of cancers, including hematologic malignancies, from diagnosis to response to therapy. The role of S100A8 and S100A9 in hematologic malignancies is highlighted due to their ability to work together or as antagonists to modify cell phenotype, including viability, differentiation, chemosensitivity, trafficking, and transcription strategies, which can lead to an oncogenic phase or reduced symptoms. In this review article, we discuss the critical roles of S100A8, S100A9, and calprotectin (heterodimer or heterotetramer forms of S100A8 and S100A9) in forming and promoting the malignant bone marrow microenvironment. We also focus on their potential roles as biomarkers and therapeutic targets in various stages of hematologic malignancies from diagnosis to treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
ORCID-Profile: Sena Kim, Jaebok Choi
Förderung
- NCI NIH HHS
- Amy Strelzer Manasevit Research Program
- Foundation for Barnes-Jewish Hospital Cancer Frontier Fund
- St. Baldrick’s Foundation
Zitieren
APA
Razmkhah, F., Kim, S., Lim, S., Dania, A. J., & Choi, J. (2023). S100A8 and S100A9 in Hematologic Malignancies: From Development to Therapy. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms241713382
Vancouver
Razmkhah F, Kim S, Lim S, Dania AJ, Choi J. S100A8 and S100A9 in Hematologic Malignancies: From Development to Therapy. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms241713382
BibTeX
@article{Razmkhah2023,
author = {Razmkhah, Farnaz and Kim, Sena and Lim, Sora and Dania, Abdul-Jalil and Choi, Jaebok},
title = {S100A8 and S100A9 in Hematologic Malignancies: From Development to Therapy},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms241713382}
}
EUVIMED